Barclays lowered the firm’s price target on Crispr Therapeutics (CRSP) to $42 from $56 and keeps an Equal Weight rating on the shares. The company’s Q1 update highlighted promising initial CTX310 Phase 1 data, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating
- CRISPR Therapeutics Reports Q1 2025 Progress and Financials
- Cathie Wood’s ARK Investment buys 329K shares of Crispr Therapeutics today
- Crispr Therapeutics price target lowered to $79 from $80 at BofA
- Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations